Rubius Therapeutics Inc. [RUBY] is -95.01% lower this YTD. Is it still time to buy?

Rubius Therapeutics Inc. [NASDAQ: RUBY] gained 6.27% or 0.03 points to close at $0.48 with a heavy trading volume of 20269654 shares. The company report on September 19, 2022 that Rubius Therapeutics to Present at Guggenheim Nantucket Therapeutics Conference.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free.


Rubius Therapeutics, Inc. (Nasdaq: RUBY), a biopharmaceutical company that is developing an entirely new class of cellular medicines called Red Cell Therapeutics™ for the treatment of cancer and autoimmune diseases, today announced that Pablo J. Cagnoni, M.D., president and chief executive officer, will participate in a fireside chat at the Guggenheim Nantucket Therapeutics Conference on Thursday, September 29, 2022, at 11:15am EDT.

A live audio webcast will be available within the Investors & Media section of the Rubius Therapeutics website. An archived replay will be accessible for 90 days following the event.

It opened the trading session at $0.5701, the shares rose to $0.5743 and dropped to $0.465, the range by which the price of stock traded the whole day. The daily chart for RUBY points out that the company has recorded -90.45% loss over the past six months. However, it is still -9.09% lower than its most recent low trading price.

If we look at the average trading volume of 3.07M shares, RUBY reached to a volume of 20269654 in the most recent trading day, which is why market watchdogs consider the stock to be active.

Here is what top equities market gurus are saying about Rubius Therapeutics Inc. [RUBY]:

Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for RUBY shares is $7.62 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on RUBY stock is a recommendation set at 2.50. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.

Guggenheim have made an estimate for Rubius Therapeutics Inc. shares, keeping their opinion on the stock as Neutral, with their previous recommendation back on September 13, 2022. While these analysts kept the previous recommendation, Morgan Stanley dropped their target price from $25 to $22. The new note on the price target was released on October 19, 2021, representing the official price target for Rubius Therapeutics Inc. stock. Previously, the target price had yet another drop from $19 to $4, while SVB Leerink kept a Mkt Perform rating on RUBY stock.

The Average True Range (ATR) for Rubius Therapeutics Inc. is set at 0.12 The Price to Book ratio for the last quarter was 0.46, with the Price to Cash per share for the same quarter was set at 1.65.

Trading performance analysis for RUBY stock

Rubius Therapeutics Inc. [RUBY] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -15.28. With this latest performance, RUBY shares dropped by -35.07% in over the last four-week period, additionally sinking by -90.45% over the last 6 months – not to mention a drop of -97.50% in the past year of trading.

Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for RUBY stock in for the last two-week period is set at 37.05, with the RSI for the last a single of trading hit 33.09, and the three-weeks RSI is set at 39.01 for Rubius Therapeutics Inc. [RUBY]. The present Moving Average for the last 50 days of trading for this stock 0.7560, while it was recorded at 0.4943 for the last single week of trading, and 3.6985 for the last 200 days.

Rubius Therapeutics Inc. [RUBY]: A deeper dive into fundamental analysis

Return on Equity for this stock declined to -122.71, with Return on Assets sitting at -65.98.

Rubius Therapeutics Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 4.60 and a Current Ratio set at 4.60.

An analysis of insider ownership at Rubius Therapeutics Inc. [RUBY]

There are presently around $38 million, or 87.20% of RUBY stock, in the hands of institutional investors. The top three institutional holders of RUBY stocks are: FLAGSHIP PIONEERING INC. with ownership of 38,506,526, which is approximately 0% of the company’s market cap and around 5.20% of the total institutional ownership; FMR LLC, holding 13,528,925 shares of the stock with an approximate value of $6.53 million in RUBY stocks shares; and BAILLIE GIFFORD & CO, currently with $2.37 million in RUBY stock with ownership of nearly -0.028% of the company’s market capitalization.

Positions in Rubius Therapeutics Inc. stocks held by institutional investors increased at the end of August and at the time of the August reporting period, where 39 institutional holders increased their position in Rubius Therapeutics Inc. [NASDAQ:RUBY] by around 4,186,148 shares. Additionally, 85 investors decreased positions by around 15,094,968 shares, while 8 investors held positions by with 59,354,896 shares. The mentioned changes placed institutional holdings at 78,636,012 shares, according to the latest SEC report filing. RUBY stock had 19 new institutional investments in for a total of 1,537,500 shares, while 57 institutional investors sold positions of 6,201,870 shares during the same period.


Please enter your comment!
Please enter your name here